Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine 
Samsung Electronics Shares Jump on HBM4 Mass Production Report 
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing 
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans 
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences 
Indian Refiners Scale Back Russian Oil Imports as U.S.-India Trade Deal Advances 
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026 
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 
Kroger Set to Name Former Walmart Executive Greg Foran as Next CEO 
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off 
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape 
Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning 
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge 
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering 
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports 
NEW YORK, May 04, 2017 -- Congressional leaders have agreed to a budget package that calls for $400 million in increased funding for Alzheimer’s disease research at the National Institutes of Health (NIH) in the fiscal year (FY) 2017 federal budget. If passed, this would put overall funding for Alzheimer’s disease research at approximately $1.4 billion for FY 2017. The Alzheimer’s Foundation of America (AFA) issued the following statement, from Bert E. Brodsky, AFA’s founder and board chairman, and Charles J. Fuschillo, Jr., AFA’s president and CEO:
“AFA applauds Congressional appropriators, including Representatives Cole and DeLauro and Senators Blunt and Murray, as well as the leaders of both the House and Senate in recognizing and addressing the growing need for Alzheimer’s disease research at NIH.
In order to achieve the goal of the national Alzheimer’s plan—to find a cure or meaningful treatment by 2025—we need to aggressively pursue a path toward that goal, and this funding increase is a step in the right direction. AFA will continue working with stakeholders, advocates, Congressional champions and the White House to ensure that finding a cure for Alzheimer’s disease remains a national priority.”
AFA—whose mission is to provide optimal care and services to individuals living with Alzheimer’s disease and related illnesses, and their families—is calling for $2 billion a year for Alzheimer’s disease research from the federal government. This $2 billion figure is the amount that leading Alzheimer’s researchers say is necessary to find a cure by 2025.
Currently, Alzheimer’s disease is the sixth leading cause of death in the United States, yet it is the only disease state in the top 10 causes of death for which there is neither a cure nor impactful treatment.
About Alzheimer’s Foundation of America (AFA):
The Alzheimer’s Foundation of America, based in New York, is a non-profit organization that unites more than 2,500 member organizations nationwide in the goal of providing optimal care and services to individuals confronting dementia, and to their caregivers and families. Its services include a national, toll-free helpline (866-232-8484) staffed by licensed social workers, educational materials, a free quarterly magazine for caregivers and “AFA Partners in Care” dementia care training for healthcare professionals. For more information about AFA, call 866-232-8484, visit www.alzfdn.org, follow us on Twitter, or connect with us on Facebook or LinkedIn.
CONTACT: Sandy Silverstein 866-232-8484, ext. 104 [email protected]
